Inhibrx Biosciences Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 4, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Market Capitalization	1,256	223	-	-
Enterprise Value	1,225	28	-	-
Last Close Price	87.41	15.40	-	-
PE Ratio	-	0.13	-	-
PS Ratio	908.05	1114.65	-	-
PB Ratio	34.41	1.67	-	-
P/TBV Ratio	34.52	1.67	-	-
EV/Sales Ratio	875.06	142.16	-	-
Debt / Equity Ratio	2.90	0.06	4.83	-0.69
Asset Turnover	0.01	0.00	0.01	-
Inventory Turnover	55.38	34.28	35.84	-
Quick Ratio	4.28	3.76	4.95	0.01
Current Ratio	4.49	3.94	5.25	0.30
Return on Equity (ROE)	-144.07%	1905.92%	-1333.38%	-
Return on Assets (ROA)	-60.97%	-67.38%	-84.42%	-
Return on Capital (ROIC)	-75.27%	-83.29%	-108.99%	-
Return on Capital Employed (ROCE)	-137.90%	-188.10%	-87.10%	2794.40%
Earnings Yield	-12.20%	757.00%	-	-
FCF Yield	-11.28%	-88.37%	-	-
Buyback Yield / Dilution	-6.72%	-27.17%	72.77%	-

Updated Nov 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q